 |
|
NIAID experts see dengue as potential threat to US public health
January 09, 2008A disease most Americans have never heard of could soon become more prevalent if dengue, a flu-like illness that can turn deadly, continues to expand into temperate climates and increase in severity, according to a new commentary by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and David M. Morens, M.D., Fauci's senior scientific advisor. Their commentary appears in the January 9 and 16 double issue of the Journal of the American Medical Association.
Previously confined to tropical and subtropical climates, the mosquito-borne illness is becoming a much more serious problem along the U.S.-Mexico border and in the commonwealth of Puerto Rico. Dengue occurs sporadically and has had a relatively small impact on the United States thus far, so the amount of dengue-related illness in this country is presently minimal. However, the disease tends to occur in explosive epidemics. Moreover, the NIAID scientists note, efforts to control the populations of mosquitoes that transmit dengue have fallen short of their goal.
These trends stimulated Drs. Fauci and Morens to call for more research to understand and combat dengue. "Widespread appearance of dengue in the continental United States is a real possibility," the NIAID scientists write in their commentary. "Worldwide, dengue is among the most important reemerging infectious diseases with an estimated 50 to 100 million annual cases-[and] 22,000 deaths." Public health officials need to take the threat seriously, the scientists assert, because no specific treatments or vaccines for dengue are available. To fight the disease, they state, "The formidable challenges of understanding dengue pathogenesis and of developing effective therapies and vaccines must be met."
Dengue (pronounced "DENG-ee") is caused by any of four related viruses transmitted to humans by the mosquitoes Aedes albopictus (nicknamed "Asian tiger mosquito") and Aedes aegypti. First seen in the United States in 1985, Ae. albopictus has been found in 36 states, while Ae. aegypti has been found in several southern states. Experience elsewhere in the world shows that where these mosquitoes go, the disease usually follows.
In their commentary, Drs. Fauci and Morens provide a historical and clinical overview of dengue; discuss the controversy about the origins and development of the most severe forms of the disease; describe the implications of dengue pathogenesis for safe vaccination strategies; and note the challenges to dengue treatment, control and prevention. The scientists highlight the hypothesis that naturally and maternally acquired dengue antibody may precipitate severe disease on subsequent infection. This hypothesis has implications for dengue vaccine development, the authors write, because a vaccine could potentially stimulate the immune system to cause more severe disease on subsequent natural infection.
Most people infected with a dengue virus have no symptoms or a mild fever. Those who do get sick sometimes experience minor bleeding, such as from the nose or gums, and frequently develop a high fever, severe headache, pain behind the eyes and in joints and muscles, and a rash. Sometimes the disease leads to leakage of blood plasma out of the circulatory system and into tissues, causing blood pressure to drop. This condition often can be reversed by giving patients fluids and electrolytes. With proper treatment, case fatality rates for severe dengue can be less than 1 percent. If left untreated, however, the person may become unresponsive, slip into a coma and possibly die. Early diagnosis and treatment of dengue are critical to preventing shock and death. The severe forms of dengue disease have been defined by the World Health Organization as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
Recognizing the threat to public health posed by dengue, NIAID allocated $33.2 million in fiscal year 2007 for nearly 60 dengue research projects, including basic research on dengue, DHF and DSS; projects to develop vaccines, diagnostics and therapeutics for the disease; and clinical trials of vaccines.
The priorities of NIAID's dengue research program include the following:
* Develop animal models to study the basic mechanisms of infection and perform preliminary tests of vaccines and therapeutics
* Design and evaluate vaccines and therapeutics
* Understand how dengue viruses can elicit antibodies-normally a form of protection against disease-that may help the viruses infect host cells and exacerbate the disease
* Learn what causes capillaries to leak plasma in DHF and DSS
* Understand the genetic factors in both people and dengue viruses that influence the severity of the disease
* Identify biological markers that might predict whether an individual is protected from dengue viruses and whether a person with dengue fever will likely develop DHF or DSS
By vigorously pursuing these research priorities, NIAID hopes to advance the development of medical tools to fight this important reemerging infectious disease.
NIH/National Institute of Allergy and Infectious Diseases
Dengue (pronounced "DENG-ee") is caused by any of four related viruses transmitted to humans by the mosquitoes Aedes albopictus (nicknamed "Asian tiger mosquito") and Aedes aegypti. First seen in the United States in 1985, Ae. albopictus has been found in 36 states, while Ae. aegypti has been found in several southern states. Experience elsewhere in the world shows that where these mosquitoes go, the disease usually follows.
In their commentary, Drs. Fauci and Morens provide a historical and clinical overview of dengue; discuss the controversy about the origins and development of the most severe forms of the disease; describe the implications of dengue pathogenesis for safe vaccination strategies; and note the challenges to dengue treatment, control and prevention. The scientists highlight the hypothesis that naturally and maternally acquired dengue antibody may precipitate severe disease on subsequent infection. This hypothesis has implications for dengue vaccine development, the authors write, because a vaccine could potentially stimulate the immune system to cause more severe disease on subsequent natural infection.
Most people infected with a dengue virus have no symptoms or a mild fever. Those who do get sick sometimes experience minor bleeding, such as from the nose or gums, and frequently develop a high fever, severe headache, pain behind the eyes and in joints and muscles, and a rash. Sometimes the disease leads to leakage of blood plasma out of the circulatory system and into tissues, causing blood pressure to drop. This condition often can be reversed by giving patients fluids and electrolytes. With proper treatment, case fatality rates for severe dengue can be less than 1 percent. If left untreated, however, the person may become unresponsive, slip into a coma and possibly die. Early diagnosis and treatment of dengue are critical to preventing shock and death. The severe forms of dengue disease have been defined by the World Health Organization as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
Recognizing the threat to public health posed by dengue, NIAID allocated $33.2 million in fiscal year 2007 for nearly 60 dengue research projects, including basic research on dengue, DHF and DSS; projects to develop vaccines, diagnostics and therapeutics for the disease; and clinical trials of vaccines.
The priorities of NIAID's dengue research program include the following:
* Develop animal models to study the basic mechanisms of infection and perform preliminary tests of vaccines and therapeutics
* Design and evaluate vaccines and therapeutics
* Understand how dengue viruses can elicit antibodies-normally a form of protection against disease-that may help the viruses infect host cells and exacerbate the disease
* Learn what causes capillaries to leak plasma in DHF and DSS
* Understand the genetic factors in both people and dengue viruses that influence the severity of the disease
* Identify biological markers that might predict whether an individual is protected from dengue viruses and whether a person with dengue fever will likely develop DHF or DSS
By vigorously pursuing these research priorities, NIAID hopes to advance the development of medical tools to fight this important reemerging infectious disease.
NIH/National Institute of Allergy and Infectious Diseases
Dengue Current Events and Dengue News RSSOn the Trail of a Vaccine for Lyme Disease: Yale Researchers Target Tick Saliva
A protein found in the saliva of ticks helps protect mice from developing Lyme disease, Yale researchers have discovered. The findings, published in the November 19 issue of Cell Host & Microbe, may spur development of a new vaccine against infection from Lyme disease, which is spread through tick bites.
Climate variability and dengue incidence
Research published this week in PLoS Medicine demonstrates associations between local rainfall and temperature and cases of dengue fever, which affects an estimated fifty million people per year worldwide.
Drug industry, nonprofits join forces to fight world's neglected diseases
Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year.
Population movement can be critical factor in dengue's spread
Human movement is a key factor of dengue virus inflow in Rio de Janeiro, according to results from researchers based at the Oswaldo Cruz Foundation (Fiocruz) in Brazil.
DNA barcodes: Creative new uses span health, fraud, smuggling, history, more
The scientific ability to quickly and accurately identify species through DNA "barcoding" is being embraced and applied by a growing legion of global authorities - from medical and agricultural researchers to police and customs authorities to palaeontologists and others.
Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice
An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.
UH Manoa researcher examines possible implications of daily commute and mosquito-borne diseases
University of Hawaii at Manoa assistant researcher Durrell Kapan recently published a paper, Man Bites Mosquito: Understanding the Contribution of Human Movement to Vector-Borne Disease Dynamics, in PLoS One. Published August 26, the paper highlights how daily commuting patterns in mega-cities may be a critically overlooked factor in understanding the resurgence of mosquito-borne diseases such as dengue fever, infecting 50-100 million people annually.
Researchers develop the first climate-based model to predict Dengue fever outbreaks
Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are the most important vector-borne viral diseases in the World.
Dengue fever costs billions in health care, lost productivity and absenteeism
Researchers at Brandeis, in collaboration with several other institutions worldwide, have pinpointed for the first time the multi-country economic costs of dengue fever, the endemic and epidemic mosquito-borne illness that is a rapidly growing public health problem in tropical and sub-tropical countries.
Visualizing virus replication in 3 dimensions
Dengue fever is the most common infectious disease transmitted by mosquitoes - some 100 million people around the world are infected. Researchers at the Hygiene Institute at Heidelberg University Hospital were the first to present a three-dimensional model of the location in the human cell where the virus is reproduced.
More Dengue Current Events and Dengue News Articles
 |
Dengue (Tropical Medicine Science and Practice) (Tropical Medicine: Science and Practice) by Scott B. Halstead (Author), Scott B. Halstead (Editor) This unique volume presents an up-to-date review of one of the world s major health problems -- diseases caused by the four dengue viruses. It begins with an insightful story of the origin of dengue disease outbreaks, including the emergence of severe and fatal dengue hemorrhagic fever. The nature, structure and biology of the four dengue viruses are described, and a major portion of the book is focused on the epidemiology of dengue as a mosquito-borne disease. This is complemented by critiques of existing mosquito control programs by three groups of outstanding authorities. The strongest element of the volume is its comprehensive description of the current understanding of dengue disease pathogenesis, followed by an analysis of the pros and cons of five of the most... |
 |
Venus on Earth by Dengue Fever "A unique and surprisingly danceable group that combines a beautiful Khmer-language vocalist from Cambodia and a quintet of seasoned locals with a knack for mixing Southeast Asian pop, Vietnam-war-era lounge music, klezmer, ska, surf rock, and Ethiopian jazz." -- SPIN psychedelic. They are world music. They are anything but mainstream. There is virtually no other band in the world playing "Khmer Rock," the style of 1960s Cambodian rock derived from Armed Forces Radio in Southeast Asia during the Vietnam War. Sophomore album Venus On Earth features eleven original songs that expand on the band's sound but will please hardcore fans of both the group and the genre. There is no other band like Dengue Fever, which garners fans in everyone from indie kids to well-heeled world music... |
 |
Dengue Fever and Other Hemorrhagic Viruses (Deadly Diseases and Epidemics) by Tritha, Ph.D. Chakraborty (Author) Dengue fever is an infectious disease found around the world that is caused by four closely related, but distinct, types of viruses commonly transmitted by Aedes aegypti mosquitoes. Triggering excessive bleeding, dengue fever, dengue hemorrhagic fever, and dengue hemorrhagic shock can be fatal. "Dengue Fever and Other Hemorrhagic Viruses" explores the biology of the dengue virus and similar viruses such as Ebola, Marburg virus, and Lassa fever, as well as their symptoms, where they are commonly found, how they are transmitted, and the efforts to treat and eradicate them.Chapters include: Ins and Outs of Dengue; Hemorrhagic Fevers; Vectors - Bugs That Carry Disease; The Immune System: Our Line of Defense; and, Vaccination - Waking Up the Army in Us. |
 |
Venus on Earth Dengue Fever (Primary Contributor) |
 |
Sleepwalking Through the Mekong Starring: Dengue Fever Studio: Allegro Media Group Release Date: 05/12/2009 Run time: 70 minutes |
 |
Escape from Dragon House by Dengue Fever "If you can imagine a band where a Cambodian beauty queen shares the stage with Rasputin, Barry White, Allen Ginsberg, Michael Hutchence, and Brian Wilson, you'd have a pretty good idea of the group Dengue Fever." -- L.A. TIMES "Her voice is swathed in reverb, becoming instantly mythic." -- THE WIRE "The culture clash inherent to this band gives its debut a dynamic flair." -- TIME OUT NEW YORK "Dengue Fever is at the vanguard of an emerging global pop sensibility, making familiar yet eerily unique music." -- KEXP Fronted by Cambodian pop star Ch'hom Nimol, who sings in Khmer, Los Angeles sextet Dengue Fever blends the rhythms of sixties Cambodian pop--heavily influenced by American surf, rock, and early psychedelic garage bands--with their own eclectic mix of... |
 |
Frontiers in Dengue Virus Research by Kathryn Hanley (Editor), Scott Weaver (Editor) |
 |
Dengue Fever: Sleep Walking Through The Mekong Starring: Chhom Nimol, Zac Holtzman, Ethan Holtzman, David Ralicke, Paul Dreux Smith Directed By: John Pirozzi Also With: John Pirozzi (Producer), Josh Otten (Producer) |
 |
Sea to Summit Personal Mosquito Shelter (Double) by Sea to Summit An indispensible item for traveling or backpacking in bug infested regions. The Sea to Summit Mosquito Net shelters are small, light and compact. Available in a Permetherin treated version. Handy stuff sack for easing packing included. Double version has 22 spreader pole that packs down to 6. |
|
World Immunization Chart, Status as per July 15, 1979 (Including geographical distribution of Dengue Fever and recommendations on preventive measures.) by International Association for Medical Assistance to Travelers |
| © 2009 BrightSurf.com |